← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
insulin (human)
A10AD01
Forms & Strengths
- U-100 solution for injection (100 units/mL) in 10 mL vials
- U-100 solution for injection (100 units/mL) in 3 mL cartridges
- U-100 solution for injection (100 units/mL) in 5 mL cartridges
- U-100 prefilled pens (3 mL, 100 units/mL)
Adult Dosing
- Initial dose: 0.5-1 unit/kg/day, subcutaneously, divided into 2-4 doses
- Titrate dose to achieve glycemic control
- Usual maintenance dose: 0.5-1.5 units/kg/day
Pediatric Dosing
- Children <1 year: 0.25-1 unit/kg/day, subcutaneously, divided into 2-4 doses
- Children 1-12 years: 0.5-1 unit/kg/day, subcutaneously, divided into 2-4 doses
- Adolescents (13-18 years): 0.5-1.5 units/kg/day, subcutaneously, divided into 2-4 doses
Indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (inadequate control with diet and/or oral hypoglycemic agents)
Mechanism of Action
- Stimulates glucose uptake in muscle and adipose tissue
- Inhibits glucose production in liver
- Regulates lipolysis and lipogenesis
Contraindications
- Hypersensitivity to insulin (human) or any excipients
- Diabetic ketoacidosis (DKA) with or without coma
Adverse Reactions
- Hypoglycemia
- Lipodystrophy at injection sites
- Weight gain
- Allergic reactions (e.g., pruritus, rash, swelling)
Drug Interactions
- Beta-blockers (masking of hypoglycemia symptoms)
- Corticosteroids, growth hormone, and oral contraceptives (increased blood glucose levels)
- Monoamine oxidase inhibitors, salicylates, and sulfonamides (increased risk of hypoglycemia)
Curated Content: Needs Vetting Before Put to Clinical Use